Indivior (NASDAQ:INDV) Hits New 52-Week High - What's Next?

Key Points

• Indivior PLC's stock price reached a new 52-week high of $17.54 during trading, closing at $17.28 with a significant trading volume of over 1.78 million shares.
• Analyst ratings have improved, with Wall Street Zen upgrading Indivior to a "strong-buy" rating, and Craig Hallum increasing its price target to $22.00.
• Institutional investors hold 60.33% of Indivior's stock, with notable increases in holdings from firms like Deerfield Management and Goldman Sachs.

Indivior PLC (NASDAQ:INDV - Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as $17.54 and last traded at $17.28, with a volume of 1787141 shares traded. The stock had previously closed at $17.09.

Wall Street Analysts Forecast Growth

INDV has been the subject of a number of recent analyst reports. Craig Hallum boosted their price objective on shares of Indivior from $15.00 to $22.00 and gave the stock a "buy" rating in a report on Monday, June 30th. Wall Street Zen upgraded shares of Indivior from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Finally, Jefferies Financial Group began coverage on shares of Indivior in a research note on Tuesday, July 22nd. They set a "buy" rating and a $20.00 target price for the company. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Indivior presently has a consensus rating of "Buy" and a consensus price target of $17.75.

Indivior Trading Up 4.2%

The business's 50 day simple moving average is $14.85 and its two-hundred day simple moving average is $11.89. The firm has a market capitalization of $2.90 billion, a PE ratio of 33.95 and a beta of 0.65.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.26 by $0.25. The firm had revenue of $302.00 million during the quarter, compared to the consensus estimate of $239.43 million. Indivior had a net margin of 6.65% and a negative return on equity of 85.50%. As a group, equities research analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current year.

Institutional Trading of Indivior

Hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its position in Indivior by 16.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company's stock worth $71,000 after purchasing an additional 666 shares during the period. Rathbones Group PLC grew its stake in Indivior by 11.6% in the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock worth $183,000 after acquiring an additional 1,483 shares in the last quarter. Two Sigma Investments LP grew its stake in Indivior by 2.1% in the 4th quarter. Two Sigma Investments LP now owns 110,880 shares of the company's stock worth $1,378,000 after acquiring an additional 2,237 shares in the last quarter. Stifel Financial Corp grew its stake in Indivior by 24.0% in the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock worth $158,000 after acquiring an additional 2,450 shares in the last quarter. Finally, PDT Partners LLC grew its stake in Indivior by 4.7% in the 4th quarter. PDT Partners LLC now owns 57,520 shares of the company's stock worth $715,000 after acquiring an additional 2,596 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company's stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.